Sunday, November 29 | 10:00 a.m.- 10:10 a.m. | S1-SSGU01-7 | Room E353B
Multiparametric MRI (mpMRI) does well for identifying clinically significant prostate cancer (csPCa) using the PI-RADS 2.1 scoring system, according to results from the ECOG-ACRIN 8171 study to be presented Sunday morning.
A team led by Rajan T. Gupta, MD, of Duke University School of Medicine in Durham, NC, found that in the overall population, mpMRI (T2W, DWI, and DCE) interpreted with PI-RADS v2.1 showed sensitivity to clinically significant prostate cancer of 84.5%, specificity of 72.2%, positive predictive value of 99.3%, and an area under the curve of 0.82. These results came from a study that assessed 807 men from 34 institutions who underwent mpMRI prior to planned surgery.
The researchers also conducted a secondary subset analysis that included 107 Black or African American men (13.3% of the cohort), finding that the diagnostic performance of mpMRI was slightly lower than in the broader study population, with an area under the curve (AUC) of 0.70, sensitivity of 74.1%, specificity of 67.3%, and a positive predictive value of 98.7%.
"Overall, these findings confirm that local site mpMRI interpretation using PI-RADS v2.1 provides accurate pre-operative characterization of csPCa in the general population, which can aid clinicians in tailoring and optimizing definitive treatment plans," Gupta and colleagues concluded. "However, the observed disparity in performance among Black or African American men highlights a critical area requiring further research to ensure equitable diagnostic efficacy across diverse patient demographics."
